ArticleJournal of immunology (Baltimore, Md. : 1950)2009
Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.
Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Article
- The Role of Interleukin-7 in the Formation of Tertiary Lymphoid Structures and Their Prognostic Value in Gastrointestinal Cancers.Journal of immunotherapy and precision oncology · 2022Review
- Article
- Study on the Inhibitory Effects of Ephedra AconiteEvidence-based complementary and alternative medicine : eCAM · 2017Article
- Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination.Mediators of inflammation · 2016Review
- Enhanced anti-tuberculosis immunity by a TAT-Ag85B protein vaccine in a murine tuberculosis model.Pathogens and global health · 2015Article
- Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.Oncoimmunology · 2014Article
- Characterization of the immune cell repertoire in the normal fallopian tube.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2014Article
- CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis.Journal of virology · 2014Article
- Article
- The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Frontiers in immunology · 2013Review
- Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells.Cancer gene therapy · 2013Article
- Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer.Cancer immunology, immunotherapy : CII · 2013Article
- Allergenic characterization of new mutant forms of Pru p 3 as new immunotherapy vaccines.Clinical & developmental immunology · 2013Article
- IL-36γ/IL-1F9, an innate T-bet target in myeloid cells.The Journal of biological chemistry · 2012Article
- Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?Immunologic research · 2011Article
- T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract.Immunologic research · 2011Article
- T-bet in disease.Nature immunology · 2011Review
- FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.The Journal of clinical investigation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
T-bet (TBX21) is a transcription factor required for the optimal development of type 1 immune responses. Although initially characterized for its intrinsic role in T cell functional polarization, endogenous T-bet may also be critical to the licensing of type 1-biasing APCs. Here, we investigated whether human dendritic cells (DC) genetically engineered to express high levels of T-bet (i.e., DC.Tbet) promote superior type 1 T cell responses in vitro. We observed that DC.Tbet were selective activators of type 1 effector T cells developed from the naive pool of responder cells, whereas DC.Tbet and control DC promoted type 1 responses equitably from the memory pool of responder cells. Naive T cells primed by (staphylococcal enterotoxin B or tumor-associated protein-loaded) DC.Tbet exhibited an enhancement in type 1- and a concomitant reduction in Th2- and regulatory T cell-associated phenotype/function. Surprisingly, DC.Tbets were impaired in their production of IL-12 family member cytokines (IL-12p70, IL-23, and IL-27) when compared with control DC, and the capacity of DC.Tbet to preferentially prime type 1 T cell responses was only minimally inhibited by cytokine (IL-12p70, IL-23, IFN-gamma) neutralization or receptor (IL-12Rbeta2, IL-27R) blockade during T cell priming. The results of transwell assays suggested the DC.Tbet-mediated effects are predominantly the result of direct DC-T cell contact or their close proximity, thereby implicating a novel, IL-12-independent mechanism by which DC.Tbets promote improved type 1 functional polarization from naive T cell responders. Given their superior type 1 polarizing capacity, DC.Tbet may be suitable for use in vaccines designed to prevent/treat cancer or infectious disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.